Several evidences suggest that NK cells can patrol the body and eliminate
tumors in their initial phases but may hardly control established solid
tumors. Multiple factors, including the transition of
tumor cells towards a proinvasive/prometastatic phenotype, the immunosuppressive effect of the tumor microenvironment, and the
tumor structure complexity, may account for limited NK cell efficacy. Several putative mechanisms of NK cell suppression have been defined in these last years; conversely, the cross talk between NK cells and
tumor cells undergoing different transitional phases remains poorly explored. Nevertheless, recent in vitro studies and immunohistochemical analyses on
tumor biopsies suggest that NK cells could not only kill
tumor cells but also influence their evolution. Indeed, NK cells may induce
tumor cells to change the expression of HLA-I, PD-L1, or NKG2D-L and modulate their susceptibility to the immune response. Moreover, NK cells may be preferentially located in the borders of
tumor masses, where, indeed,
tumor cells can undergo Epithelial-to-Mesenchymal Transition (EMT) acquiring prometastatic phenotype. Finally, the recently highlighted role of
HMGB1 both in EMT and in amplifying the recruitment of NK cells provides further hints on a possible effect of NK cells on
tumor progression and fosters new studies on this issue.